51. Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
- Author
-
Hiroshi Ogura, Tomoya Hirose, Hiroki Takahashi, Takashi Kojima, Masahiro Ojima, Youhei Nakamura, Takeshi Shimazu, and Kang Jinkoo
- Subjects
medicine.medical_specialty ,Resuscitation ,Hemodynamics ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,law.invention ,C1-inhibitor ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,medicine ,Vascular permeability ,biology ,business.industry ,Septic shock ,Research ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Shock ,030208 emergency & critical care medicine ,lcsh:RC86-88.9 ,medicine.disease ,Intensive care unit ,Shock (circulatory) ,biology.protein ,Observational study ,medicine.symptom ,business ,C1 inhibitor (C1-INH) - Abstract
Background C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeability and anti-inflammatory functions. The objective of this study was to clarify the serial change of C1-INH in patients with sepsis and evaluate the relationship with the shock severity. Methods This was a single-center, prospective, observational study. We serially examined C1-INH activity values (normal range 70–130%) in patients with sepsis admitted into the intensive care unit of the Trauma and Acute Critical Care Center at Osaka University Hospital (Osaka, Japan) during the period between January 2014 and August 2015. We defined “refractory shock” as septic shock unresponsive to conventional therapy such as adequate fluid resuscitation and vasopressor therapy to maintain hemodynamics. Results Serial changes of C1-INH were evaluated in 40 patients with sepsis (30 men, 10 women; 30 survivors, 10 non-survivors; mean age, 70 ± 13.5 years). We divided the patients into three groups: non-shock group (n = 14), non-refractory shock group (n = 13), and refractory shock group (n = 13: 3 survivors, 10 non-survivors). In the non-shock group, C1-INH was 107.3 ± 26.5% on admission and 104.2 ± 22.3% on day 1, and it increased thereafter to 128.1 ± 26.4% on day 3, 138.3 ± 21.2% on day 7, and 140.3 ± 12.5% on day 14 (p
- Published
- 2018